Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Can-Fite BioPharma ( (CANF) ).
On January 14, 2026, Can-Fite BioPharma Ltd. announced that board member Yaacov Goldman resigned from the company’s Board of Directors and all board committees, effective immediately, citing personal reasons and affirming that his departure did not stem from any disagreement over the company’s operations, policies, or practices. The change, formally reported in a January 16, 2026 SEC filing, represents a governance update for the biopharmaceutical company but does not signal a dispute or strategic shift, limiting near-term implications for corporate policy and offering reassurance to investors and other stakeholders about the stability of management oversight.
The most recent analyst rating on (CANF) stock is a Hold with a $0.20 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue, and negative free cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Valuation impact is neutral because P/E and dividend data are not available.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is an Israel-based biopharmaceutical company, listed in the United States as a foreign private issuer, that develops pharmaceutical products and operates under the regulatory framework of the U.S. Securities Exchange Act for foreign issuers.
Average Trading Volume: 500,821
Technical Sentiment Signal: Sell
Current Market Cap: $5.63M
See more insights into CANF stock on TipRanks’ Stock Analysis page.